Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 17/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4964660 | 0.84 | TLR8 (0.61) | TLR8TLR7 | |
| SCHEMBL4970650 | 0.77 | KMT2A (0.40) | TLR8TLR7TP53ALOX5EPHX2 | |
| SCHEMBL2807850 | 0.72 | TLR8 (0.57) | TLR8TLR7 | |
| SCHEMBL2810620 | 0.70 | TLR8 (0.64) | TLR8TLR7 | |
| SCHEMBL6997420 | 0.70 | TLR8 (0.61) | TLR8TLR7 | |
| SCHEMBL1527927 | 0.67 | TLR8 (0.72) | TLR8TLR7 | |
| SCHEMBL1527985 | 0.67 | TLR8 (0.59) | TLR8TLR7 | |
| SCHEMBL2808735 | 0.67 | TLR8 (0.72) | TLR8TLR7 | |
| SCHEMBL5767654 | 0.66 | TLR8 (0.56) | TLR8TLR7GAA | |
| Hydrochloric Acid SCHEMBL2807427 | 0.66 | TLR8 (0.70) | TLR8TLR7RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378102-B2 | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100240693-A1 | Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240693-A1 | Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods | IL4, IL2, TH | TLR8 203/4885TLR7 43/4885TP53 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.